Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2017

01-04-2017 | Letter to Editor

Diagnosis of Interstitial Lung Disease Caused by Possible Hypersensitivity Pneumonitis in a Child: Think CGD

Authors: Saliha Esenboga, Nagehan Emiralioglu, Deniz Cagdas, Baran Erman, Martin De Boer, Berna Oguz, Nural Kiper, İlhan Tezcan

Published in: Journal of Clinical Immunology | Issue 3/2017

Login to get access

Abstract

Interstitial lung disease (ILD) is a rare and heterogeneous group of disorder affecting the lung parenchyma and has a detrimental effect on gas exchange. Chronic granulomatous disease (CGD), when it affects primarily lungs, may cause ILD. We report a 16-year-old patient with CGD caused by homozygous deletion of NCF1 who atypically presented with ILD. The patient had many pigeons and was a pigeon breeder. Exacerbated clinical symptoms were linked to hypersensitivity pneumonitis (HP), and the patient was suggested to keep away from pigeons. In addition to allergen avoidance and prophylactic antibacterial therapy, treatment with corticosteroids and hydroxychloroquine was started for mainly obstructive and persistant symptoms of ILD. CGD is known to cause a hyperinflammatory state and the patients present with excessive granuloma formation and HP. Control of inflammation either by avoidance of allergen exposure and by anti-inflammatory drugs is necessary for the relief of symptoms.
Literature
1.
go back to reference Soares JJ, Deutsch GH, Moore PE, Fazili MF, Austin ED, Brown RF, Sokolow AG, Hilmes MA, Young LR. Childhood interstitial lung diseases: an 18-year retrospective analysis. Pediatrics. 2013;132(4):684–91.CrossRefPubMedPubMedCentral Soares JJ, Deutsch GH, Moore PE, Fazili MF, Austin ED, Brown RF, Sokolow AG, Hilmes MA, Young LR. Childhood interstitial lung diseases: an 18-year retrospective analysis. Pediatrics. 2013;132(4):684–91.CrossRefPubMedPubMedCentral
2.
go back to reference Buchvald F, Petersen BL, Damgaard K, Deterding R, Langston C, Fan LL, Deutsch GH, Dishop MK, Kristensen LA, Nielsen KG. Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis. PediatrPulmonol. 2011;46(11):1098–107. Buchvald F, Petersen BL, Damgaard K, Deterding R, Langston C, Fan LL, Deutsch GH, Dishop MK, Kristensen LA, Nielsen KG. Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis. PediatrPulmonol. 2011;46(11):1098–107.
3.
go back to reference Mahdaviani SA, Mohejerani SA, Rezaei N, et al. Pulmonary manifestations of chronic granulomatous disease. Expert Rev Clin Immunol. 2013;9:153–60.CrossRefPubMed Mahdaviani SA, Mohejerani SA, Rezaei N, et al. Pulmonary manifestations of chronic granulomatous disease. Expert Rev Clin Immunol. 2013;9:153–60.CrossRefPubMed
4.
go back to reference Leiding JW, Holland SM. Chronic granulomatous disease. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, StephensK, editors. GeneReviews1[Internet]. Seattle, WA: University of Washington;2012. pp. 1993–2014 Leiding JW, Holland SM. Chronic granulomatous disease. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, StephensK, editors. GeneReviews1[Internet]. Seattle, WA: University of Washington;2012. pp. 1993–2014
5.
go back to reference Holland SM. Chronic granulomatous disease. Clin Rev AllergyImmunol. 2010;38(1):3–10.CrossRef Holland SM. Chronic granulomatous disease. Clin Rev AllergyImmunol. 2010;38(1):3–10.CrossRef
6.
go back to reference van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, et al. Reactive oxygen species independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010;107(7):3030–3.CrossRefPubMedPubMedCentral van de Veerdonk FL, Smeekens SP, Joosten LA, Kullberg BJ, Dinarello CA, van der Meer JW, et al. Reactive oxygen species independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease. Proc Natl Acad Sci U S A. 2010;107(7):3030–3.CrossRefPubMedPubMedCentral
7.
go back to reference Turul ÖT, Türkkanı AG, Tezcan İ, Köker MY, Metin A, Yel L, Ersoy F, Sanal Ö. Clinical features of chronic granulomatous disease: a series of 26 patients from a single center. Turk J Pediatr. 2010;52:576–81. Turul ÖT, Türkkanı AG, Tezcan İ, Köker MY, Metin A, Yel L, Ersoy F, Sanal Ö. Clinical features of chronic granulomatous disease: a series of 26 patients from a single center. Turk J Pediatr. 2010;52:576–81.
8.
go back to reference De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122(6):1097–103.CrossRefPubMedPubMedCentral De Ravin SS, Naumann N, Cowen EW, Friend J, Hilligoss D, Marquesen M, et al. Chronic granulomatous disease as a risk factor for autoimmune disease. J Allergy Clin Immunol. 2008;122(6):1097–103.CrossRefPubMedPubMedCentral
9.
10.
go back to reference Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. ClinMol Allergy. 2011;9(1):10. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. ClinMol Allergy. 2011;9(1):10.
11.
go back to reference Kawai T, Watanabe N, Yokoyama M, Nakazawa Y, Goto F, Uchiyama T, Higuchi M, Maekawa T, Tamura E, Nagasaka S, Hojo M, Onodera M. Interstitial lung disease with multiple microgranulomas in chronic granulomatous disease. J Clin Immunol. 2014;34(8):933–40.CrossRefPubMed Kawai T, Watanabe N, Yokoyama M, Nakazawa Y, Goto F, Uchiyama T, Higuchi M, Maekawa T, Tamura E, Nagasaka S, Hojo M, Onodera M. Interstitial lung disease with multiple microgranulomas in chronic granulomatous disease. J Clin Immunol. 2014;34(8):933–40.CrossRefPubMed
12.
go back to reference Katsuya Y, Hojo M, Kawai S, Kawai T, Onodera M, Sugiyama H. Chronic granulomatous disease with pulmonary mass-like opacities secondary to hypersensitivity pneumonitis: a case report. J Med Case Rep. 2014;8:242.2.CrossRef Katsuya Y, Hojo M, Kawai S, Kawai T, Onodera M, Sugiyama H. Chronic granulomatous disease with pulmonary mass-like opacities secondary to hypersensitivity pneumonitis: a case report. J Med Case Rep. 2014;8:242.2.CrossRef
13.
go back to reference Noel N, Mahlaoui N, Blnache S, et al. Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. J Allergy Clin Immunol. 2013;132(4):997–1000.CrossRefPubMed Noel N, Mahlaoui N, Blnache S, et al. Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. J Allergy Clin Immunol. 2013;132(4):997–1000.CrossRefPubMed
Metadata
Title
Diagnosis of Interstitial Lung Disease Caused by Possible Hypersensitivity Pneumonitis in a Child: Think CGD
Authors
Saliha Esenboga
Nagehan Emiralioglu
Deniz Cagdas
Baran Erman
Martin De Boer
Berna Oguz
Nural Kiper
İlhan Tezcan
Publication date
01-04-2017
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2017
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-017-0376-8

Other articles of this Issue 3/2017

Journal of Clinical Immunology 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.